TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05136508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
Study: NCT05568446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social virtual reality
Description: The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional social skills
Description: The participants will receive eight training sessions in 4 weeks (2 sessions per week). Each session is about 20 minutes.
Study: NCT05918796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone
Study: NCT04742907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU-100
Description: Treatment with investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU-100
Description: Treatment with investigational product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo product
Study: NCT04871022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double layer closure of the hysterotomy
Description: Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Purse closure of the hysterotomy
Description: Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
Study: NCT04940026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amcenestrant
Description: Tablet Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-SAR439859 microtracer
Description: Solution for infusion Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-SAR439859
Description: Powder for oral solution Oral
Study: NCT05560438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tyromotion Amadeo and Armeo Senso
Description: Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
Study: NCT04846309

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic. Subjects with tumors identified by imaging as hypoxic will be treated with a higher dose of radiation therapy. Tumors will be defined as being hypoxic if FMISO accumulation occurs as demonstrated by standardized uptake value (SUV) uptake in the tumor.
Study: NCT05583487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led progressive mobility protocol
Description: The nurse-led mobility progression protocol incorporates a checklist for four primary team members belonging to each discipline to follow before, during, and after providing mobility for each patient. It outlines steps to progress patient mobility from in-bed mobility activities to out-of-bed activities as tolerated. This protocol intervention was created and designed based upon a review of previously conducted studies' interventions and findings, as well as expert guidelines established in the literature. Furthermore, multidisciplinary experts at the medical center who work with ventilated neurosurgery patients were consulted to form the protocol to further establish hemodynamic, neurological, respiratory, and physiological patient safety parameters. This intervention has not been implemented in previous studies and will be piloted for this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: For the purposes of the current study, the control group of multidisciplinary teams requested to mobilize the ventilated neurosurgery patient, may also consist of the primary nurse, RT, PT, and PCT. They will be asked to progressively mobilize the patient to the best of their ability according to standard of care procedures, incorporating any resources the medical center provides including, but not limited to, written information, equipment, ThinkLift, etc.
Study: NCT04703088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: 2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: 2 mL of 0,9% Saline in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
Study: NCT05129748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate + Mannitol
Description: Drug delivery will be sequential, where Mannitol will be infused over 30 minutes and Sodium Thiosulfate will be infused over 15 minutes.
Study: NCT05046223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.
Description: cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The responses to bronchoscopic insertion for bronchoscopic interventions such asTBNA, Cryotherapy, etc.
Description: cough response, the changes of BP, HR, SpO2, Trans dermal CO2 during bronchoscopic interventions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postoperative recovery
Description: anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative recovery
Description: anesthetic recovery in postoperative care unit recovery of swallowing by questionnaire in POD1
Study: NCT05255523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
Study: NCT04729725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-TGF-beta Monoclonal Antibody SAR-439459
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV
Study: NCT04879056

Intervention type: DIAGNOSTIC_TEST
Intervention: PIPS 5.1
Description: Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.

Intervention type: DIAGNOSTIC_TEST
Intervention: PIPS 5.1
Description: Description: Scanning glass slides on PIPS 5.1. This intervention will be applied in the arm of intra-system and the arm of inter-system.
Study: NCT05086497

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole Brain Spectroscopy Imaging Array Mapping Layout
Description: All study participants will receive whole brain spectroscopy imaging as a part of MRI study time points. Participants assigned to the advanced MR imaging array mapping layout study arm will receive tumor treating fields mapping from Optune that is created from the spectroscopy sequences or advanced MR imaging. Participants assigned to the conventional array mapping layout will still receive advanced imaging sequences or spectroscopy imaging at all time points.
Study: NCT06148207

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]BF3-BPA Injection for PET Imaging
Description: Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]BF3-BPA Injection for PET Imaging
Description: Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
Study: NCT04706962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH1902
Description: Intravenous infusion
Study: NCT06353594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: Coronary percutaneous revascularization
Study: NCT05153577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A: $5 produce box
Description: Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
Study: NCT04846309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMISO PET CT
Description: Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic.
Study: NCT05153577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B: $10 produce box
Description: Participants receive free weekly produce boxes delivered to their home for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study. Participants also complete survey at the beginning, middle, and end of the produce delivery program.
Study: NCT06042959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: We used laughter yoga to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
Study: NCT04988867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofinetide
Description: Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Study: NCT06373523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg daily will be given to the treatment arm.Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Replacement daily
Description: Levothyroxine Replacement daily for 28 weeka

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine Replacement daily
Description: Levothyroxine Replacement daily for 28 weeka
Study: NCT05963139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
Study: NCT06226103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Computerized Cognitive Training
Description: Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercises and Brain health lectures
Description: Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks
Study: NCT05743803

Intervention type: OTHER
Intervention: Sensititization campaign on preoperative fasting rules
Description: * Planned and repeated mandatory on site lecture about pre-operative guidelines for surgeons, anesthetists and paramedics.~* Reminder display in surgical wards and consults.~* Individualized fasting cards for patients.~* Short message service reminder on pre-operative fasting rules for patients.~* Medical fasting prescription with clear fasting times.
Study: NCT04743830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment (Bobath) + Scapular Training
Description: The Bobath concept for 40 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed with 20 minutes scapular training including scapular exercise such as Proprioceptive Neuromuscular Facilitation (PNF), dynamic hug, towel-wall slide, scapular punch exercises etc. 3 days a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Treatment (Bobath)
Description: The Bobath concept for 60 minutes will be formed according to the needs of the individual and involve the upper limb, trunk and lower limb. It will be performed 3 days a week for 8 weeks.
Study: NCT05294601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training
Description: high intensity exercise with games

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium-Intensity Interval Training
Description: medium intensity exercise with games
Study: NCT04972786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS pulses will be delivered through an air-cooled coil in either a figure-eight or double-cone shape, with the latter being particularly useful for targeting deeper structures such as dACC. The first phase of the TMS protocol will involve a standardized motor-thresholding procedure, wherein peripheral responses evoked by single TMS pulses are recorded via an electromyographic recording device. In this phase, the TMS coil's stimulation intensity is titrated to a level that is comfortable yet effective at reliably exciting neuronal populations orthogonal to the coil (50% motor-evoked potentials ≥50 microvolts; typical duration≈20-40 mins). Then repetitive TMS (rTMS) will be administered to a pre-determined cortical target based on the individual's pre-TMS fMRI scan using a Localite Neuronavigation system (duration≈10-20 mins). The rTMS protocol will involve the delivery of a train of TMS pulses over a cortical target prior to performance of behavioral tasks during a post-rTMS fMRI scan.
Study: NCT05706779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Oral Capsule + Cetuximab
Description: Encorafenib: 4 capsules 75 mg/day (300 mg) , 7 days/7 during 6 weeks Cetuximab: 500mg/m2 intravenous route every 2 weeks (D1, D14, D28), for 3 cycles over 4 weeks.
Study: NCT04809831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse
Description: Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)
Description: Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.
Study: NCT06527170

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Each patient undergoes bariatric surgery. Each patient is diagnosed before surgery for erectile dysfunction. Similar tests are done 1 year after
Study: NCT05324111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kardia 6L
Description: The Kardia 6L has CE marking. The purpose of this study is to extend the use of this device by a simple modification using existing equipment in the department. The device will be connected to the left leg electrodes using standard clinical crocodile clips and the other electrode applied to the chest in V1 and V6 positions to acquire the modified V1 and V6 leads
Study: NCT05298202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: application of capsaicin gel from shoulder to wrist and mid thigh to ankle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Gel
Description: application of hypoallergenic gel from shoulder to wrist and mid thigh to ankle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: treadmill walking 3.5 mph at 5% grade

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: treadmill walking 3.5 mph at 5% grade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot environment
Description: 38°C, 60% relative humidity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot environment
Description: 38°C, 60% relative humidity
Study: NCT04862325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: 1. High-intensity endurance exercise training program and physical activity promotion remotely controlled with ICT (information and communications technologies).~2. Nutritional counselling to achieve protein intake of 1.5-1.8 g/kg and whey protein supplements.~3. Psychological intervention including motivational interview, mindfulness meditation and cognitive behavioral therapy
Study: NCT05588349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling + stretching exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: Stretching exercise only
Study: NCT06133335

Intervention type: OTHER
Group type: OTHER
Intervention: Periodontal examination
Description: Periodontal examination is performed using PCP UNC15 periodontal probe (common diagnostic method not added by research).~Gingival smear from various points in the oral cavity. This intervention consists in a smear of gingival area with an absorbent paper point into the space between the gum and the tooth (Jourdain et al. 2018). The objective of this technique is to remove the various elements of the periodontal pocket and in particular the desquamated cells.